NCT02332642已完成不适用
Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Immuno-monitoring
研究概览
简要总结
This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and activity.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically defined metastatic melanoma patients (AJCC stage IV)
- •aged 18 to 80 years
- •at least one prior systemic anti-melanoma therapy; if BRAFV600 positive, at least one prior BRAFi therapy
排除标准
- •therapy-naive patients
- •any contra-indications for (specific) systemic chemotherapy
结局指标
主要结局
Immuno-monitoring
时间窗: Immediate
次要结局
未报告次要终点
研究者
Dr. Christoffer Gebhardt
Principal Investigator
Universitätsmedizin Mannheim
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal AntibodiesMetastatic MelanomaNCT02626065Hospices Civils de Lyon32
已完成
不适用
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic MelanomaMetastatic MelanomaNCT03225365Hospices Civils de Lyon5
已完成
2 期
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic MelanomaNeoplasm MetastasisMelanomaNCT00001832National Cancer Institute (NCI)170
已完成
1 期
Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma PatientsMalignant MelanomaNCT00306566Cytos Biotechnology AG
已完成
2 期
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced MelanomaMelanomaNCT00080353National Cancer Institute (NCI)58